Dr Rink-Jan Lohman
Dr

Rink-Jan Lohman

Email: 

Availability

Dr Rink-Jan Lohman is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), University of Melbourne
  • Doctor of Philosophy, University of Melbourne

Research interests

  • Pharmacology

  • pharmacokinetics

  • inflammatory disease

  • peptides as disease modifying drugs

  • oral bioavailablity and transporters

Search Professor Rink-Jan Lohman’s works on UQ eSpace

45 works between 2009 and 2024
All (45) Journal Article (32) Book Chapter (2) Conference Publication (11)

1 - 20 of 45 works

2024

Journal Article

A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis

Poon, Eunice K., Liu, Ligong, Wu, Kai‐Chen, Lim, Junxian, Sweet, Matthew J., Lohman, Rink‐Jan, Iyer, Abishek and Fairlie, David P. (2024). A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis. British Journal of Pharmacology, 181 (23), 4804-4821. doi: 10.1111/bph.17306

A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis

2024

Book Chapter

Integration of dendrimer-based delivery technologies with computational pharmaceutics and their potential in the era of nanomedicine

Tupally, Karnaker Reddy, Seal, Prasenjit, Pandey, Preeti, Lohman, Rink-Jan, Smith, Sean, Ouyang, Defang and Parekh, Haredra (2024). Integration of dendrimer-based delivery technologies with computational pharmaceutics and their potential in the era of nanomedicine. Exploring computational pharmaceutics - AI and modeling in Pharma 4.0. (pp. 328-378) edited by Defang Ouyang. Hoboken, NJ, United States: Wiley. doi: 10.1002/9781119987260.ch10

Integration of dendrimer-based delivery technologies with computational pharmaceutics and their potential in the era of nanomedicine

2023

Conference Publication

Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency

Saifuddin, D., Lohman, R.-J., Tupally, K., Parekh, H. and Cabot, P. (2023). Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing.

Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency

2023

Journal Article

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

Galante, Priscilla, Campos, Gabriel A. A., Moser, Jacqueline C. G., Martins, Danubia B., Dos Santos Cabrera, Marcia P., Rangel, Marisa, Coelho, Luiza C., Simon, Karina S., Amado, Veronica M., de A. I. Muller, Jessica, Koehbach, Johannes, Lohman, Rink-Jan, Cabot, Peter J., Vetter, Irina, Craik, David J., Toffoli-Kadri, Monica C., Monge-Fuentes, Victoria, Goulart, Jair T., Schwartz, Elisabeth F., Silva, Luciano P., Bocca, Anamelia L. and Mortari, Márcia R (2023). Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom. Scientific Reports, 13 (1) 12491, 1-15. doi: 10.1038/s41598-023-38828-w

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

2023

Journal Article

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

Lohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J and Parekh, Harendra S (2023). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. Frontiers in Pharmacology, 14 1150313, 1150313-14. doi: 10.3389/fphar.2023.1150313

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

2022

Journal Article

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

Lohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J. and Parekh, Harendra S. (2022). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. British Journal of Pharmacology, 180 (1), 129-129. doi: 10.1111/bph.15862

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

2022

Journal Article

Fabrication and Characterization of Clozapine Nanoemulsion Sol–Gel for Intranasal Administration

Tan, Madeleine S. A., Pandey, Preeti, Lohman, Rink-Jan, Falconer, James R., Siskind, Dan J. and Parekh, Harendra S. (2022). Fabrication and Characterization of Clozapine Nanoemulsion Sol–Gel for Intranasal Administration. Molecular Pharmaceutics, 19 (11), 4055-4066. doi: 10.1021/acs.molpharmaceut.2c00513

Fabrication and Characterization of Clozapine Nanoemulsion Sol–Gel for Intranasal Administration

2021

Conference Publication

Novel opioid peptides as allosteric modulators of nociception

Saifuddin, Danial, Lohman, Rink-Jan, Tupally, Karnaker Reddy, Parekh, Harendra S. and Cabot, Peter J. (2021). Novel opioid peptides as allosteric modulators of nociception. ASMR medical research week: Queensland virtual symposium, Online, 9-10 June 2021.

Novel opioid peptides as allosteric modulators of nociception

2020

Journal Article

Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition

Kennedy, Amanda J., Sundström, Linda, Geschwindner, Stefan, Poon, Eunice K. Y., Jiang, Yuhong, Chen, Rongfeng, Cooke, Rob, Johnstone, Shawn, Madin, Andrew, Lim, Junxian, Liu, Qingqi, Lohman, Rink-Jan, Nordqvist, Anneli, Fridén-Saxin, Maria, Yang, Wenzhen, Brown, Dean G., Fairlie, David P. and Dekker, Niek (2020). Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Communications Biology, 3 (1) 782, 782. doi: 10.1038/s42003-020-01504-0

Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition

2020

Journal Article

Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activity

Rowley, Jessica A., Reid, Robert C., Poon, Eunice K. Y., Wu, Kai-Chen, Lim, Junxian, Lohman, Rink-Jan, Hamidon, Johan K., Yau, Mei-Kwan, Halili, Maria A., Durek, Thomas, Iyer, Abishek and Fairlie, David P. (2020). Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activity. Journal of Medicinal Chemistry, 63 (2) acs.jmedchem.9b00927, 529-541. doi: 10.1021/acs.jmedchem.9b00927

Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activity

2020

Journal Article

High cell permeability does not predict oral bioavailability for analogues of cyclic heptapeptide sanguinamide A

Nielsen, Daniel S., Lohman, Rink-Jan, Hoang, Huy N., Fairlie, David P. and Hill, Timothy A. (2020). High cell permeability does not predict oral bioavailability for analogues of cyclic heptapeptide sanguinamide A. Australian Journal of Chemistry, 73 (4), 344-351. doi: 10.1071/ch19479

High cell permeability does not predict oral bioavailability for analogues of cyclic heptapeptide sanguinamide A

2019

Journal Article

Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities

Lohman, Rink-Jan, Nielsen, Daniel S., Kok, W. Mei, Hoang, Huy N., Hill, Timothy A. and Fairlie, David P. (2019). Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities. Chemical Communications, 55 (89), 13362-13365. doi: 10.1039/c9cc06234c

Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities

2019

Journal Article

Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney

Ma, Frank Y., Han, Yingjie, Ozols, Elyce, Chew, Phyllis, Vesey, David A., Gobe, Glenda C., Morais, Christudas, Lohman, Rink-Jan, Suen, Jacky Y., Johnson, David W., Fairlie, David P. and Nikolic-Paterson, David J. (2019). Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. Nephrology, 24 (9) nep.13635, 983-991. doi: 10.1111/nep.13635

Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney

2019

Journal Article

Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy

Starobova, H., Mueller, A., Allavena, R., Lohman, R. J., Sweet, M. J. and Vetter, I. (2019). Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy. Frontiers in Neuroscience, 13 (JUN) 653, 653. doi: 10.3389/fnins.2019.00653

Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy

2019

Journal Article

Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis

Han, Yingjie, Tian, Lifang, Ma, Frank, Tesch, Greg, Vesey, David A., Gobe, Glenda C., Lohman, Rink-Jan, Morais, Christudas, Suen, Jacky Y., Fairlie, David P. and Nikolic-Paterson, David J. (2019). Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis. Clinical and Experimental Pharmacology and Physiology, 46 (5) 1440-1681.13077, 456-464. doi: 10.1111/1440-1681.13077

Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis

2019

Journal Article

Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular

Khalil, Zeinab G., Hill, Timothy A., De Leon Rodriguez, Luis M., Lohman, Rink-Jan, Hoang, Huy N., Reiling, Norbert, Hillemann, Doris, Brimble, Margaret A., Fairlie, David, Blumenthal, Antje and Capon, Robert J. (2019). Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular. Antimicrobial Agents and Chemotherapy, 63 (3) e01773-18. doi: 10.1128/AAC.01773-18

Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular

2018

Conference Publication

PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney

Han, Y., Ma, F., Ozols, E., Chew, P., Vesey, D., Gobe, G., Morais, C., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2018). PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney. 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Sydney, Australia, 8–12 September 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/nep.13441

PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney

2017

Journal Article

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

Lohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, 351. doi: 10.1038/s41467-017-00414-w

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

2017

Journal Article

An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice

Do, Anh, Reid, Robert C., Lohman, Rink-Jan, Sweet, Matthew J., Fairlie, David P. and Iyer, Abishek (2017). An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice. The Journal of Pharmacology and Experimental Therapeutics, 360 (1), 140-151. doi: 10.1124/jpet.116.236711

An HDAC6 inhibitor confers protection and selectively inhibits B-cell infiltration in DSS-induced colitis in mice

2016

Journal Article

Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2

Lieu, T., Savage, E., Zhao, P., Edgington-Mitchell, L., Barlow, N., Bron, R., Poole, D. P., Mclean, P., Lohman, R. -J., Fairlie, D. P. and Bunnett, N. W. (2016). Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2. British Journal of Pharmacology, 173 (18), 2752-2765. doi: 10.1111/bph.13554

Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2

Availability

Dr Rink-Jan Lohman is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Dr Rink-Jan Lohman directly for media enquiries about:

  • animal ethics
  • animal research
  • anti-inflammatory
  • arthritis
  • colitis
  • drugs
  • inflammatory bowel disease
  • inflammatory disease
  • laboratory
  • mice
  • peptide
  • peptides
  • pharmacokinetics
  • pharmacology
  • ranting
  • rats
  • Science and technology

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au